Alexion

David W. Keiser to Retire as President of Alexion

Co-Founder Remains On Board Of Directors CHESHIRE, Conn., Nov. 11 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. ("Alexion," the "Company," Nasdaq: ALXN) announced today that David W. Keiser, the Company's Chief Operating Officer since 1992 and President since 2002, will retire by t...

PDL BioPharma Announces Second Quarter 2009 Financial Results

...ynagis(R), which is marketed by MedImmune, Inc. Also included in the second quarter revenue was the second and final installment of $12.5 million from alexion Pharmaceuticals, Inc. based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sou...

Alexion Pharmaceuticals To Report Fourth Quarter and Full Year 2008 Results on February 12, 2009

... CHESHIRE, Conn., Jan. 12 /PRNewswire-FirstCall/ -- alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), today announced that the Company w...before the financial markets open. Following the release of the financials, alexion management will conduct a conference call and audio web cast on Thursday, F...

Alexion to Present at the 27th Annual JP Morgan Healthcare Conference

... CHESHIRE, Conn., Jan. 5 /PRNewswire-FirstCall/ -- alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Dr. Leonard Bell, Chief Executive Officer of alexion Pharmaceuticals, will present at the 27th Annual JP Morgan Healthcare Confe...

Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute

... alexion Licenses PDL's Queen et al. Patents for Soliris(R)...all/ -- PDL BioPharma, Inc. (Nasdaq: PDLI ) and alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today joi...er the agreements announced today, PDL has granted alexion a license under certain claims in the Queen patent...

Alexion to Present at the 20th Annual Piper Jaffray Health Care Conference

... CHESHIRE, Conn., Nov. 25 /PRNewswire-FirstCall/ -- alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Dr. Leonard Bell, Chief Executive Officer of alexion Pharmaceuticals, will present at the 20th Annual Piper Jaffray Health Care ...

Researchers to Present Additional Data on Soliris(R) (eculizumab) for the Treatment of PNH at the ASH Annual Meeting

...full prescribing information at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and...ormulations of eculizumab for additional clinical indications. In addition, alexion is pursuing development of an anti-CD200 monoclonal antibody as a treatment...

Alexion to Present at Investor Conferences

...., Nov. 4 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Leonard Bell, M.D., Chief Executive Officer of alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Deutsche Bank and the other by Credit Suisse. Dr. Bell will pre...

Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)

...ntain Quality Resources, Inc. announced today that alexion Pharmaceuticals has chosen Blue Mountain Regulator...work orders can be viewed from within SAP. About alexion Pharmaceuticals alexion Pharmaceuticals, Inc., established in 1992, is eng...

Vertos Medical Inc. Completes Series C Financing

...merous successful companies including GeneOhm Sciences (acquired by Becton Dickinson), Incyte Pharmaceuticals (Nasdaq: INCY), NuVasive (Nasdaq: NUVA), alexion Pharmaceuticals (Nasdaq: ALXN), Celgene (Nasdaq: CELG), Amicus Therapeutics (Nasdaq: FOLD), SemperCare (acquired by Select Medical), Genomic Health (N...

Alexion in Medical Technology

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... CHESHIRE, Conn., Dec. 8 /PRNewswire-FirstCall/ -- alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today repo...eutical and Medical Device Administration (PMDA). alexion expects to include data from the AEGIS study in an...ng information at www.soliris.net . About alexion ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

...mab), a terminal complement inhibitor developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) for the tr...ng information at www.soliris.net . About alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...

Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody

...Cells and Uses Thereof." The patent is assigned to alexion and includes claims that encompass the composition...rrhage, infection and death. (4) About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...h serious and life-threatening medical conditions. alexion is engaged in the discovery, development and comme...

InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

...el, Switzerland, September 28, 2008. The only treatment currently available for PNH patients is an anti-C5 antibody Soliris(TM) (eculizumab) sold by alexion Pharmaceuticals, Inc. rC3-1 promotes the enzymatic partial depletion of C3, the hub of the complement cascade. Complement protein C3 is the master r...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

...n anemia they experience." Soliris, developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) was approve...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...h serious and life-threatening medical conditions. alexion is engaged in the discovery, development and comme...

Alexion Completes Enrollment in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...h serious and life-threatening medical conditions. alexion is engaged in the discovery, development and comme...st product, Soliris, for all patients with PNH and alexion began commercial sale of Soliris in the U.S. durin...

Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan

...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...h serious and life-threatening medical conditions. alexion is engaged in the discovery, development and comme...st product, Soliris, for all patients with PNH and alexion began commercial sale of Soliris in the U.S. durin...

PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity

... said Leonard Bell, MD, Chief Executive Officer of alexion Pharmaceuticals. "The results presented today prov...s will have access to it." Soliris, developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), is the fir...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...

Long-Term Soliris(R) Therapy Improved or Stabilized Kidney Function in Patients With PNH

...Soliris, Hemolysis and PNH Soliris, developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), is the fir... said Leonard Bell, MD, Chief Executive Officer of alexion Pharmaceuticals. "As we understand more about the ...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...

Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients

...Soliris, Hemolysis and PNH Soliris, developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), is the fir...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biotechnology company w...lings with the Securities and Exchange Commission. alexion does not intend to update any of these forward-loo...

Alexion in Biological Technology

PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million

...gis(R), which is marketed by MedImmune. Also included in the second quarter revenue estimate is the second and final installment of $12.5 million from alexion based on the companies' December 2008 settlement and license agreement. When compared with 2008, royalty revenue for foreign sourced sales was negativ...

PDL BioPharma Announces First Quarter 2009 Financial Results

... common stock per $1,000 principal amount of the 2012 Notes. -- alexion agreed to pay PDL $25 million, of which it paid $12.5 million in Jan... MedImmune from being entitled to a lower royalty rate based on the alexion settlement. -- Approval for Raptiva(R) was suspended in the European U...

Soliris(R) Reduced Measures of Thrombosis and Inflammation, and Decreased Indicators of Pulmonary Hypertension, in Studies of Patients with PNH

...mab), a terminal complement inhibitor developed by alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ), was obser...ng information at www.soliris.net . About alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...

Connecticut Technology Council Honors UHY LLP Tech Top 40 Winners

...M Technologies, Inc., Stamford-Category Winner Perimeter eSecurity, Milford The TNS Group, Stamford VIRTERA, Shelton Life Sciences Companies alexion Pharmaceuticals Inc., Cheshire-Category Winner CAS Medical Systems, Inc., Branford Defibtech, LLC, Guilford IMS Health Inc., Norwalk Z-Medica ...

Alexion Reports Third Quarter 2008 Results

...: For the three months ended September 30, 2008, alexion reported total revenues of $76.5 million from net ...ris. Third Quarter 2008 GAAP Financial Results alexion reported GAAP net income for the third quarter of ...ment for Patients with PNH In the third quarter, alexion began analysis of the data collected during its AE...

Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners

...nc., Stamford Perimeter eSecurity, Milford The TNS Group, Stamford VIRTERA, Shelton Life Sciences Companies CAS Medical Systems, Inc., Branford alexion Pharmaceuticals Inc., Cheshire Defibtech, LLC, Guilford IMS Health Inc., Norwalk Z-Medica Corporation, Wallingford New Media/Internet/Telecom Com...

Alexion's Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product

...ion at http://www.soliris.net . About Alexion alexion Pharmaceuticals, Inc. is a biopharmaceutical compa...h serious and life-threatening medical conditions. alexion is engaged in the discovery, development and comme...st product, Soliris, for all patients with PNH and alexion began commercial sale of Soliris in the U.S. durin...

Prix Galien USA Announces 2008 Final Candidates

...useum of Natural History in New York. The final candidates for the Prix Galien USA 2008 awards are: -- Actelion Ltd. - Ventavis(R) (Iloprost) -- alexion Pharmaceuticals - Soliris(TM) -- BioMarin Pharmaceutical Inc. - Nagalzyme(R) -- Bristol-Myers Squibb - Sprycel(R) -- Boehringer Ingelheim - Apti...

Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference

...n., June 18 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today announced that Dr. Leonard Bell, Chief Executive Officer of alexion Pharmaceuticals, will present at the Jefferies & Co. 2nd Annual Healthcare Conference in New York City at 4:15 p.m., ET on Wednesday, June 25, 2008. ...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

... BIOTECH AB (OMX Nordic Exchange Stockholm: ACTI) alexion PHARMACEUTICALS INC. (NASDAQ: ALXN ) COMBINATORX... HealthShares(TM) Cardiology Index (HRD) Drop alexion PHARMACEUTICALS INC. (NASDAQ: ALXN ) AMYLIN PHAR...HHQ) Drop ADOLOR CORPORATION (NASDAQ: ADLR ) alexion PHARMACEUTICALS INC. (NASDAQ: ALXN ) ALKERMES IN...